Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

Platinum‐based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaoliang, Kim, In‐Kyu, Kallakury, Bhaskar, Chahine, Joeffrey J., Iwama, Eiji, Pierobon, Mariaelena, Petricoin, Emanuel, McCutcheon, Justine N., Zhang, Yu‐Wen, Umemura, Shigeki, Chen, Vincent, Wang, Changli, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024728/
https://www.ncbi.nlm.nih.gov/pubmed/33320980
http://dx.doi.org/10.1002/1878-0261.12882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024728/
https://www.ncbi.nlm.nih.gov/pubmed/33320980
http://dx.doi.org/10.1002/1878-0261.12882

Ejemplares similares